Inventor · disambiguated record
Margaret A. Shipp
Also filed as: SHIPP MARGARET · SHIPP MARGARET A
15 granted patents·9 pending applications·17 citations·filing 1999–2023
88Inventor score
Files withDANA FARBER CANCER INST INC15SHIPP MARGARET A4BROAD INST INC2BRIGHAM & WOMENS HOSPITAL INC1UNIV BOSTON1
Top patents by PatentIndex Score
24 records- 0183US9206427B2Compositions, kits, and methods for the modulation of immune responses using galectin-1SHIPP MARGARET A·Filed 2008·Granted Dec 8, 2015·4 cites·6 claims
- 0282US10844126B2Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1DANA FARBER CANCER INST INC·Filed 2018·Granted Nov 24, 2020·1 cites·18 claims
- 0382US8968740B2Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1SHIPP MARGARET A·Filed 2010·Granted Mar 3, 2015·7 cites·14 claims
- 0476US10519238B2Anti-galectin-1 monoclonal antibodies and fragments thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Dec 31, 2019·2 cites·17 claims
- 0572US11723972B2Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1DANA FARBER CANCER INST INC·Filed 2019·Granted Aug 15, 2023·0 cites·8 claims
- 0672US7112420B2Lymphoma associated molecules and uses thereforDANA FARBER CANCER INST INC·Filed 2001·Granted Sep 26, 2006·2 cites·11 claims
- 0771US11673956B2Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1DANA FARBER CANCER INST INC·Filed 2020·Granted Jun 13, 2023·0 cites·4 claims
- 0868US10456465B2Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1DANA FARBER CANCER INST INC·Filed 2015·Granted Oct 29, 2019·1 cites·22 claims
- 0966US11446309B2Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitorsDANA FARBER CANCER INST INC·Filed 2014·Granted Sep 20, 2022·0 cites·6 claims
- 1058US7858742B2Lymphoma associated molecules and uses thereforDANA FARBER CANCER INST INC·Filed 2004·Granted Dec 28, 2010·0 cites·7 claims
- 1157US2024052428A1Compositions and methods for characterizing lymphoma and related conditionsBROAD INST INC·Filed 2023·Application pending·0 cites
- 1257US2021100813A1Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitorsDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1356US2024117440A1Panels and methods for treatment of diffuse large b-cell lymphomaBROAD INST INC·Filed 2023·Application pending·0 cites
- 1456US2019212330A1Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1SHIPP MARGARET A·Filed 2018·Application pending·0 cites
- 1555US7632660B2Lymphoma associated molecules and uses thereforDANA FARBER CANCER INST INC·Filed 2005·Granted Dec 15, 2009·0 cites·5 claims
- 1652US9939428B2Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1SHIPP MARGARET A·Filed 2008·Granted Apr 10, 2018·0 cites·16 claims
- 1750US2018223288A1Compositions and methods for the modulation of dna damage responses using bal1 and bbapDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 1849US9840708B2Compositions and methods for the modulation of DNA damage responses using BAL1 and BBAPDANA FARBER CANCER INST INC·Filed 2012·Granted Dec 12, 2017·0 cites·13 claims
- 1949US2016187340A1Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1DANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2046US2003194701A1Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysisFiled 2001·Application pending·0 cites
- 2143US9890429B2Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancerDANA FARBER CANCER INST INC·Filed 2013·Granted Feb 13, 2018·0 cites·20 claims
- 2234US2020270702A1Classification of diffuse large b-cell lymphomaUNIV BOSTON·Filed 2017·Application pending·0 cites
- 2333US2017029904A1Classification of myc-driven b-cell lymphomasBRIGHAM & WOMENS HOSPITAL INC·Filed 2015·Application pending·0 cites
- 2427US6870040B1Nucleic acid sequence encoding lymphoma associated molecule BALDANA FARBER CANCER INST INC·Filed 1999·Granted Mar 22, 2005·0 cites·6 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →